title: Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab.
abstract: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population.
  
  
  
  Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (ΔmSASSS) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study.
  
  
  
  Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ΔmSASSS were positively correlated in Korean AS patients (p< 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0.
  
  
  
  In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Jeong Seok
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Yeong Wook
authors.initials: YW
authors.lastname: Song
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Hanyang University Seoul Hospital, Seoul, Korea.
authors.forename: Tae Hwan
authors.initials: TH
authors.lastname: Kim
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, Korea.
authors.forename: Won Tae
authors.initials: WT
authors.lastname: Chung
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
authors.forename: Seung Geun
authors.initials: SG
authors.lastname: Lee
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Sung Hwan
authors.initials: SH
authors.lastname: Park
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
authors.forename: Gwan Gyu
authors.initials: GG
authors.lastname: Song
authors.affiliation: Janssen Korea, Medical Affairs, Seoul, Korea.
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Yu
authors.affiliation: Department of Biostatistics, Janssen Research & Development, LLC, Spring House, PA, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Xu
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Lee
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011859:Radiography; D056910:Republic of Korea; D012720:Severity of Illness Index; D013131:Spine / Q000000981:diagnostic imaging / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000000981:diagnostic imaging / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; C529000:golimumab
keywords: Disease progression; Golimumab; Spondylitis, ankylosing